IDEAYA Biosciences, Inc. $IDYA Shares Purchased by UBS Group AG

UBS Group AG raised its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 2.7% in the 4th quarter, Holdings Channel reports. The firm owned 1,085,632 shares of the company’s stock after purchasing an additional 29,055 shares during the quarter. UBS Group AG’s holdings in IDEAYA Biosciences were worth $37,530,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of IDYA. Vanguard Group Inc. boosted its holdings in shares of IDEAYA Biosciences by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 5,019,324 shares of the company’s stock valued at $173,518,000 after buying an additional 97,116 shares during the period. Baker BROS. Advisors LP raised its stake in IDEAYA Biosciences by 54.6% during the third quarter. Baker BROS. Advisors LP now owns 3,275,444 shares of the company’s stock worth $89,125,000 after acquiring an additional 1,156,716 shares during the period. Fiera Capital Corp raised its stake in IDEAYA Biosciences by 20.0% during the third quarter. Fiera Capital Corp now owns 1,837,967 shares of the company’s stock worth $50,011,000 after acquiring an additional 305,698 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in IDEAYA Biosciences by 4.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,238,094 shares of the company’s stock worth $26,025,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Candriam S.C.A. boosted its stake in IDEAYA Biosciences by 10.8% in the third quarter. Candriam S.C.A. now owns 1,012,967 shares of the company’s stock valued at $27,563,000 after acquiring an additional 98,567 shares during the period. 98.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity at IDEAYA Biosciences

In related news, Director Jeffrey Stein purchased 50,000 shares of IDEAYA Biosciences stock in a transaction dated Monday, March 2nd. The stock was bought at an average cost of $32.96 per share, with a total value of $1,648,000.00. Following the purchase, the director owned 54,281 shares in the company, valued at approximately $1,789,101.76. The trade was a 1,167.95% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Wedbush increased their price target on IDEAYA Biosciences from $52.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 14th. The Goldman Sachs Group increased their target price on IDEAYA Biosciences from $31.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Tuesday, April 21st. Mizuho reduced their price target on shares of IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Wall Street Zen upgraded shares of IDEAYA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. Fifteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, IDEAYA Biosciences has a consensus rating of “Moderate Buy” and an average price target of $50.69.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock opened at $28.24 on Friday. IDEAYA Biosciences, Inc. has a 1-year low of $16.84 and a 1-year high of $39.28. The company has a market capitalization of $2.48 billion, a P/E ratio of -17.65 and a beta of -0.04. The business’s fifty day moving average price is $32.00 and its two-hundred day moving average price is $32.96.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The company had revenue of $6.56 million for the quarter, compared to analyst estimates of $5.04 million. The firm’s quarterly revenue was down 39.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.82) EPS. On average, research analysts expect that IDEAYA Biosciences, Inc. will post -4.15 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.